Prognostic factors and survival in patients with stage IV pancreatic cancer

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter T. Alexa
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors T. Alexa1, S.-. Bulai2, R. Huluta Alexandra2, L. Miron1
  • 1Regional Institute of Oncology Iasi, Iasi, Romania, /
  • 2University of Medicine and Pharmacy Gr T Popa Iasi, Iasi, Romania, /

Abstract

Although global statistics show that pancreatic cancer is only the 13th most common malignant tumor, it ranks the fourth in terms of mortality (1). Most of the pancreatic cancers are diagnosed in advanced stages, which greatly limits the role of surgery and radiotherapy in this setting. There have been little to no improvements in pancreatic cancer management in the past years and the 5 year survival rate, estimated by studies to be around 5%, has remained constant despite intensive research (2). The aim of our study was to assess the survival of pancreatic cancer patients treated in our department, to correlate it with pre-treatment patient's data and to determine if there is a chemotherapy regimen that improves survival when compared with gemcitabine monotherapy in patients not eligible for FOLFIRINOX.